In contrast to above stated findings, Hundemer et al. (2021) showed a decrease in cardiac events (composite of MI, coronary revascularisation, congestive heart failure or atrial fibrillation) when comparing alpha-1 antagonist treatment with other BP lowering drug treatment regimes (HR 0.92, 95% CI 0.89 – 0.95) [32] whereas Hiremath et al. (2019) demonstrated a slight but insignificant increase focusing on women only (HR 1.06, 95% CI 0.99 – 1.13) [54]. This evidence concerns the gene PSMA6 and atrial fibrillation.